[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 48, "title": "CEO, President & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 716404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 565684, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Pine", "age": 48, "title": "Senior Vice President of Business Development Advisor", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.66, "open": 0.62, "dayLow": 0.62, "dayHigh": 0.7045, "regularMarketPreviousClose": 0.66, "regularMarketOpen": 0.62, "regularMarketDayLow": 0.62, "regularMarketDayHigh": 0.7045, "payoutRatio": 0.0, "beta": 0.273, "volume": 191205, "regularMarketVolume": 191205, "averageVolume": 2730814, "averageVolume10days": 6847420, "averageDailyVolume10Day": 6847420, "bid": 0.6716, "ask": 0.7267, "bidSize": 2, "askSize": 3, "marketCap": 16933402, "fiftyTwoWeekLow": 0.556, "fiftyTwoWeekHigh": 2.75, "allTimeHigh": 129540.0, "allTimeLow": 0.556, "fiftyDayAverage": 0.95802, "twoHundredDayAverage": 0.989855, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2729401, "profitMargins": 0.0, "floatShares": 7968360, "sharesOutstanding": 24214788, "sharesShort": 24913, "sharesShortPriorMonth": 108195, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.62511003, "heldPercentInstitutions": 0.07116, "shortRatio": 0.3, "shortPercentOfFloat": 0.0027, "impliedSharesOutstanding": 24197809, "bookValue": 0.261, "priceToBook": 2.6793103, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -16216000, "trailingEps": -0.95, "lastSplitFactor": "1:8", "lastSplitDate": 1703116800, "enterpriseToEbitda": -0.158, "52WeekChange": -0.71428573, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 0.6993, "targetHighPrice": 21.0, "targetLowPrice": 3.0, "targetMeanPrice": 13.75, "targetMedianPrice": 15.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 14283000, "totalCashPerShare": 0.59, "ebitda": -17228000, "totalDebt": 79000, "quickRatio": 1.694, "currentRatio": 1.737, "debtToEquity": 1.248, "returnOnAssets": -0.58407, "returnOnEquity": -1.68181, "freeCashflow": -11055375, "operatingCashflow": -16310000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": 5.95454, "regularMarketPrice": 0.6993, "esgPopulated": false, "corporateActions": [], "postMarketTime": 1763168335, "regularMarketTime": 1763154000, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "shortName": "MetaVia Inc.", "longName": "MetaVia Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "postMarketChangePercent": -3.0459056, "postMarketPrice": 0.678, "postMarketChange": -0.021300018, "regularMarketChange": 0.0393, "regularMarketDayRange": "0.62 - 0.7045", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2730814, "fiftyTwoWeekLowChange": 0.1433, "fiftyTwoWeekLowChangePercent": 0.25773382, "fiftyTwoWeekRange": "0.556 - 2.75", "fiftyTwoWeekHighChange": -2.0507, "fiftyTwoWeekHighChangePercent": -0.74570906, "fiftyTwoWeekChangePercent": -71.42857, "dividendDate": 1577750400, "earningsTimestampStart": 1755001800, "earningsTimestampEnd": 1755520200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.95, "fiftyDayAverageChange": -0.25871998, "fiftyDayAverageChangePercent": -0.270057, "twoHundredDayAverageChange": -0.290555, "twoHundredDayAverageChangePercent": -0.2935329, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroBo Pharmaceuticals, Inc.", "nameChangeDate": "2025-11-14", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "displayName": "MetaVia", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]